Aeglea BioTherapeutics, Inc. (AGLE) [Rocket]

Overview

Aeglea BioTherapeutics, Inc. (AGLE)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/06/2023	S-1/A	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
10/05/2023	8-K	Entry into a Material Definitive Agreement  Interactive Data
08/11/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/11/2023	8-K	Quarterly results
08/11/2023	8-K	Termination of a Material Definitive Agreement  Interactive Data
08/07/2023	PRE 14A	Form PRE 14A - Other preliminary proxy statements:
08/07/2023	S-3	Form S-3 - Registration statement under Securities Act of 1933:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-05-20	Dec-31-19	Dec-31-18
Revenues	2.3	2.3	18.7	18.7	0.0	59.6	0.0	3.9
Revenue growth	-87.6%	-87.6%		-68.6%			-100.0%	-25.3%
Cost of goods sold	0.0	87.1	0.0	84.4	0.0	81.5	0.0	0.0
Gross profit	2.3	-84.8	18.7	-65.6	0.0	-21.8	0.0	3.9
Gross margin	100.0%	-3640.2%	100.0%	-350.3%		-36.6%		100.0%
Selling, general and administrative	87.1		84.4		81.5
Research and development							64.6	36.7
General and administrative		28.5		27.3		21.8	15.7	12.6
EBIT	-84.0	-84.8	-65.7	-65.6	-80.9	-81.5	-80.3	-45.5
EBIT margin	-3604.7%	-3640.2%	-350.3%	-350.3%		-136.6%		-1169.3%
Pre-tax income	-84.0	-84.0	-65.7	-65.7	-80.9	-80.9	-78.3	-44.3
Income taxes	-0.1	-0.1	0.1	0.1	0.0	0.0	0.0	0.0
Tax rate	0.2%	0.2%			0.0%	0.0%	0.0%	0.0%
Net income	-83.8	-83.8	-65.8	-65.8	-80.9	-80.9	-78.3	-44.3
Net margin	-3598.8%	-3598.8%	-351.1%	-351.1%		-135.6%		-1140.6%

Diluted EPS	($0.99)	($0.99)	($1.00)	($1.00)	($1.52)	($1.52)	($2.45)	($2.13)
Shares outstanding (diluted)	84.3	84.3	65.7	65.7	53.4	53.4	31.9	20.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.